George Raad, MD
Family Medicine · Charlotte, NCNPI 1679513998
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 955 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,698 and has fallen 58.8% since, to $1,112 in 2025. Among family medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 955 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- AstraZeneca$1K
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Astellas Pharma US Inc$987
- plus $8K from 51 others
Across 746 payments — averaging $10,257 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$5.8M
- Bavarian Nordic A/s$848K
- AbbVie$388K
- GSK$156K
- AstraZeneca$137K
- Regeneron$86K
- plus $243K from 7 others
What the payments were for
- Travel & lodging$7975%
- Food & beverage$14,70292%
- Education$4213%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$15,940 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $63,059 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 432 | $62,089 |
| EliquisApixaban | 72 | $56,719 |
| MounjaroTirzepatide | 42 | $44,091 |
| XareltoRivaroxaban | 63 | $34,090 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $30,995 |
| FarxigaDapagliflozin Propanediol | 28 | $30,974 |
| JardianceEmpagliflozin | 38 | $30,562 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $26,743 |
| LinzessLinaclotide | 39 | $25,118 |
| RybelsusSemaglutide | 12 | $24,806 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 36 | $23,491 |
| JanuviaSitagliptin Phosphate | 21 | $21,497 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $21,069 |
| EntrestoSacubitril/Valsartan | 17 | $15,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,261 | $87,86565 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $36 | $62,089432 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Synjardy Xr | $658 | $57,703100 claims |
| PfizerEliquis | $1,999 | $56,71972 claims |
| MerckJanumet, Januvia, Janumet Xr | $496 | $54,66153 claims |
| Lilly USA, LLCMounjaro | $1,118 | $44,09142 claims |
| AstraZenecaFarxiga, Symbicort | $1,497 | $38,13156 claims |
| Johnson & JohnsonXarelto | $665 | $34,09063 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $779 | $30,99522 claims |
| AbbVieLinzess | $1,266 | $25,11839 claims |
| GSKTrelegy Ellipta | $193 | $21,06924 claims |
| NovartisEntresto | $448 | $15,10217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Charlotte
- Kevin SodenCharlotte$558K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Thomas BarringerCharlotte$138K
- William LarsenCharlotte$74K
- William LongCharlotte$66K
- Steven BauerCharlotte$22K
- Tagbo EkwonuCharlotte$20K
- Rhett BrownCharlotte$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.